This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144:1941-53. doi: 10.1002/ijc.31937FerlayJColombetMSoerjomataramIMathersCParkinDMPiñerosMet alEstimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInt J Cancer201914419415310.1002/ijc.3193730350310Open DOISearch in Google Scholar
Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. doi: 10.1515/raon-2017-0008ZadnikVPrimicZakelj MLokarKJarmKIvanusUZagarTCancer burden in Slovenia with the time trends analysisRadiol Oncol201751475510.1515/raon-2017-0008533017428265232Open DOISearch in Google Scholar
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402-16. doi: 10.1001/ jama.2017.7112KuchenbaeckerKBHopperJLBarnesDRPhillipsKAMooijTMRoos-BlomMJet alRisks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriersJAMA201731724021610.1001/jama.2017.711228632866Open DOISearch in Google Scholar
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-22. doi: 10.1093/jnci/djt095MavaddatNPeockSFrostDEllisSPlatteRFinebergEet alCancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACEJ Natl Cancer Inst20131058122210.1093/jnci/djt09523628597Open DOISearch in Google Scholar
Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30. doi: 10.1086/375033AntoniouAPharoahPDPNarodSRischHAEyfjordJEHopperJLet alAverage risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studiesAm J Hum Genet20037211173010.1086/375033118026512677558Open DOISearch in Google Scholar
Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, at al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2018; 150: 85-91. doi: 10.1016/j.ygyno.2018.05.011KotsopoulosJGronwaldJKarlanBRosenBHuzarskiTMollerPat alAge-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutationGynecol Oncol2018150859110.1016/j.ygyno.2018.05.01129793803Open DOISearch in Google Scholar
Guidelines for assessment of ovarian cancer patients [Slovenian]. Ljubljana: Institute of Oncology Ljubljana; 2016. [cites 2019 Nov 13]. Available from: https://www.onko-i.si/dejavnosti/zdravstvena-dejavnost/priporocila-in-klinicne-poti/priporocilaGuidelines for assessment of ovarian cancer patients [Slovenian]LjubljanaInstitute of Oncology Ljubljana2016[cites 2019 Nov 13]. Available fromhttps://www.onko-i.si/dejavnosti/zdravstvena-dejavnost/priporocila-in-klinicne-poti/priporocilaSearch in Google Scholar
Guidelines for diagnosis and treatment of breast cancer. [cites 2019 Nov 14]. Ljubljana: Institute of Oncology Ljubljana; 2018. Available from: https:// www.onko-i.si/fileadmin/onko/datoteke/Smernice/Smernice_diagnostike_in_zdravljenja_raka_dojk_2018.pdfGuidelines for diagnosis and treatment of breast cancer[cites 2019 Nov 14]LjubljanaInstitute of Oncology Ljubljana2018. Available fromhttps://www.onko-i.si/fileadmin/onko/datoteke/Smernice/Smernice_diagnostike_in_zdravljenja_raka_dojk_2018.pdfSearch in Google Scholar
Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-93. doi: 10.1200/JCO.2008.18.1107LevanonKCrumCDrapkinRNew insights into the pathogenesis of serous ovarian cancer and its clinical impactJ Clin Oncol20082652849310.1200/JCO.2008.18.1107265208718854563Open DOISearch in Google Scholar
Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutations. Gynecol Oncol 2018; 150: 79-84. doi: 10.1016/j.ygyno.2018.04.564NebgenDRHurteauJHolmanLLBradfordAMunsellMFSoletskyBRet alBilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutationsGynecol Oncol2018150798410.1016/j.ygyno.2018.04.56429735278Open DOISearch in Google Scholar
Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52-6. doi: 10.1006/gyno.2002.6779LeeperKGarciaRSwisherEGoffBGreerBPaleyPPathologic findings in prophylactic oophorectomy specimens in high-risk womenGynecol Oncol20028752610.1006/gyno.2002.677912468342Open DOISearch in Google Scholar
Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-90. doi: 10.1200/JCO.2007.12.2622CallahanMJCrumCPMedeirosFKindelbergerDWElvinJAGarberJEet alPrimary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reductionJ Clin Oncol20072539859010.1200/JCO.2007.12.262217761984Open DOISearch in Google Scholar
Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes and 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 2009; 17: 1381-5. doi: 10.1038/ejhg.2009.60EvansDGClaytonRDonnaiPShentonALallooFRisk-reducing surgery for ovarian cancer: outcomes and 300 surgeries suggest a low peritoneal primary riskEur J Hum Genet2009171381510.1038/ejhg.2009.60298667119367322Open DOISearch in Google Scholar
Reitsma W, De Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJE. Support of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013; 49: 132-41. doi: 10.1016/j.ejca.2012.07.021ReitsmaWDeBock GHOosterwijkJCBartJHollemaHMouritsMJESupport of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimensEur J Cancer2013491324110.1016/j.ejca.2012.07.02122921157Open DOISearch in Google Scholar
Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG An Int J Obstet Gynaecol 2011; 118: 814-24. doi: 10.1111/j.1471-0528.2011.02920ManchandaRAbdelraheimAJohnsonMRosenthalANBenjaminEBrunellCet alOutcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation statusBJOG An Int J Obstet Gynaecol20111188142410.1111/j.1471-0528.2011.02920Open DOISearch in Google Scholar
Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013; 129: 364-71. doi.: org/10.1016/j.ygyno.2013.01.029PowellCBSwisherEMCassIMcLennanJNorquistBGarciaRLet alLong term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomyGynecol Oncol201312936471org/10.1016/j.ygyno.2013.01.029Open DOISearch in Google Scholar
Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group trial GOG-0199. J Clin Oncol 2014; 32: 3275-83. doi: 10.1200/JCO.2013.54.1987ShermanMEPiedmonteMMaiPLIoffeOBRonnettBMVanLe Let alPathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group trial GOG-0199J Clin Oncol20143232758310.1200/JCO.2013.54.1987417852425199754Open DOISearch in Google Scholar
Thompson C, McCormick C, Kamran W, O’Riain C, Norris L, Gallagher D, et al. Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes. Ir J Med Sci 2018; 187: 789-94. doi: 10.1007/s11845-017-1717-6ThompsonCMcCormickCKamranWO’RiainCNorrisLGallagherDet alRisk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomesIr J Med Sci20181877899410.1007/s11845-017-1717-629299762Open DOISearch in Google Scholar
Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, et al. Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series. Anticancer Res 2017; 37: 5241-48. doi: 10.21873/anticanres.11948RicciardiETomaoFAlettiGBazzuriniLBoccioloneLBoveriSet alRisk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective seriesAnticancer Res20173752414810.21873/anticanres.1194828870960Open DOISearch in Google Scholar
Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up. Gynecol Oncol 2019; 153: 326-34. doi: 10.1016/j. ygyno.2019.03.003BlokFDasguptaSDinjensWNMRoesEMvanBeekhuizen HJEwing-GrahamPCRetrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-upGynecol Oncol20191533263410.1016/j.ygyno.2019.03.00330894273Open DOISearch in Google Scholar
Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol 2016; 143: 231-35. doi: 10.1016/j. ygyno.2016.08.336ZakhourMDanovitchYLesterJRimelBJWalshCSLiAJKarlanBYCassIOccult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriersGynecol Oncol20161432313510.1016/j.ygyno.2016.08.33627623252Open DOISearch in Google Scholar
Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D. A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy. Int J Surg Case Rep 2018; 52: 107-10. doi: 10.1016/j.ijscr.2018.10.014GiannosAStavrouSDouskosADrakakisPLoutradisDA salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancyInt J Surg Case Rep2018521071010.1016/j.ijscr.2018.10.014619760530340058Open DOISearch in Google Scholar
Clarke BA, Crum CP, Nucci, MR, Oliva MR. Protocol for the examination of specimens from patients with carcinoma of the fallopian tube. Based on AJCC/UICC TNM, 7th edition, and FIGO 2006 Annual Report. [cites 2019 Nov 15]. Available from: http://webapps.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/FallopianTube_13protocol_3101.pdfClarkeBACrumCPNucciMROlivaMRProtocol for the examination of specimens from patients with carcinoma of the fallopian tubeBased on AJCC/UICC TNM, 7th edition, and FIGO 2006 Annual Report. [cites 2019 Nov 15]Available fromhttp://webapps.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/FallopianTube_13protocol_3101.pdfSearch in Google Scholar
Finch APM, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32: 1547-53. doi: 10.1200/ JCO.2013.53.2820FinchAPMLubinskiJMøllerPSingerCFKarlanBSenterLet alImpact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutationJ Clin Oncol20143215475310.1200/JCO.2013.53.2820402657824567435Open DOISearch in Google Scholar
Domchek SM, Friebel TM, Singer CF, Evans DG, Henry T, Isaacs C, et al. Europe PMC funders group association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-75. doi: 10.1001/jama.2010.1237DomchekSMFriebelTMSingerCFEvansDGHenryTIsaacsCet alEurope PMC funders group association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalityJAMA20103049677510.1001/jama.2010.1237294852920810374Open DOISearch in Google Scholar
Patrono MG, Corzo C, Iniesta M, Ramirez PT. Management of pre-invasive lesions. Clin Obstet Gynecol 2017; 60: 771-9. doi: 10.1097/ GRF.0000000000000316PatronoMGCorzoCIniestaMRamirezPTManagement of pre-invasive lesionsClin Obstet Gynecol201760771910.1097/GRF.000000000000031628957950Open DOISearch in Google Scholar
Genetic/Familial High-Risk Assessment: Breast and Ovarian, version 3.2019, NCCN Guidelines, January 18, 2019. [cites 2019 Nov 15]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#detectionGenetic/Familial High-Risk Assessment: Breast and Ovarian, version 3.2019, NCCN Guidelines, January 182019[cites 2019 Nov 15]. Available fromhttps://www.nccn.org/professionals/physician_gls/default.aspx#detectionSearch in Google Scholar
Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, et al. Clinical and pathological characteristics of incidental diagnostic early occult malignancy after risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Int J Gynecol Cancer 2016; 26: 233-9. doi: 10.1097/ IGC.0000000000000624LavieOMoskovizMGAuslenderRGemerOBittermanAYounesGet alClinical and pathological characteristics of incidental diagnostic early occult malignancy after risk-reducing salpingo-oophorectomy in BRCA mutation carriersInt J Gynecol Cancer201626233910.1097/IGC.000000000000062426807561Open DOISearch in Google Scholar
Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 2014; 132: 280-6. doi: 10.1016/j.ygyno.2013.12.009ConnerJRMeserveEPizerEGarberJRohMUrbanNet alOutcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutationsGynecol Oncol2014132280610.1016/j.ygyno.2013.12.009393211324333842Open DOISearch in Google Scholar
Drescher CW, Anderson GL. The yet unrealized promise of ovarian cancer screening. JAMA Oncol 2018; 4: 456-7. doi: 10.1001/jamaoncol.2018.0028DrescherCWAndersonGLThe yet unrealized promise of ovarian cancer screeningJAMA Oncol20184456710.1001/jamaoncol.2018.002829450480Open DOISearch in Google Scholar
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015; 313: 1347-61. doi: 10.1001/ jama.2014.5985RebbeckTRMitraNWanFSinilnikovaOMHealeySMcGuffogLet alAssociation of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancerJAMA201531313476110.1001/jama.2014.5985453770025849179Open DOISearch in Google Scholar
Stegel V, Krajc M, Zgajnar J, Teugels E, De Grève J, Hočevar M, et al. The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet 2011; 12: 9. doi: 10.1186/1471-2350-12-9StegelVKrajcMZgajnarJTeugelsEDe GrèveJHočevarMet alThe occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian populationBMC Med Genet201112910.1186/1471-2350-12-9302593921232165Open DOISearch in Google Scholar
